| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 8.3 | 7.4 |
| Profit before tax | -6.4 | -8.5 |
| Net income | -6.5 | -8.5 |
| EPS (diluted, $ a share) | $-0.54 | $-1.59 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +12.3% |
|---|---|
| Operating margin | -79.0% |
10-Q filed with the SEC, NASDAQ: BNGO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Bionano Genomics, Inc.: key numbers
- Share price
- $0.9400Close, Nov 16
- Market cap
- $13.1M
- Shares outstanding
- 13.99MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Bionano Genomics, Inc.
All →Bionano Genomics Earnings Call: Key Takeaways
BioNANO delivered 12% revenue growth driven by record flow cell sales and improved gross margins, while navigating supply constraints and targeting EBITDA neutrality by 2027.
- Call
- Nov 10, 2026, 4:30 PM ET
Bionano Genomics Financial Results
Bionano Genomics reported Q3 2026 revenue of $8.3 million, a 12% increase year-over-year, driven by a 24% rise in consumables revenue. The company reiterated its full-year 2026 revenue guidance of $31 million to $33 million and highlighted progress in the clinical adoption of its optical genome mapping (OGM) technology.
- Term
- Q3 2026
“Our third quarter results reflect the momentum building across our business and the broader genomics community, further accelerating the adoption of optical genome mapping (OGM) in clinical and commercial settings.”
Al Luderer, Ph.D., chairman and interim chief executive officer
“Coverage and regulatory progress this quarter helped build a clearer reimbursement pathway for OGM-based testing, which we expect to support broader clinical adoption over time.”
Al Luderer, Ph.D., chairman and interim chief executive officer
Bionano Genomics Investor Presentation
Bionano Genomics Chairman and Interim CEO Al Luderer is presenting at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company filed its conference presentation deck as an exhibit, which includes updates on its business strategy, optical genome mapping (OGM) adoption, and cost-saving initiatives. The presentation also addresses the company's focus on extending its cash runway and reaching a pathway to profitability.
- Counterparty
- H.C. Wainwright